Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Change in Account Payables (2020 - 2025)

Aytu Biopharma (AYTU) has disclosed Change in Account Payables for 9 consecutive years, with -$1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Account Payables rose 40.3% to -$1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$384000.0, a 116.59% decrease, with the full-year FY2025 number at $287000.0, up 113.82% from a year prior.
  • Change in Account Payables was -$1.1 million for Q4 2025 at Aytu Biopharma, down from $1.7 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $6.6 million in Q4 2021 to a low of -$9.9 million in Q3 2021.
  • A 5-year average of -$186789.5 and a median of $398000.0 in 2025 define the central range for Change in Account Payables.
  • Peak YoY movement for Change in Account Payables: soared 375.51% in 2021, then tumbled 1174.63% in 2025.
  • Aytu Biopharma's Change in Account Payables stood at $6.6 million in 2021, then plummeted by 167.24% to -$4.4 million in 2022, then increased by 9.42% to -$4.0 million in 2023, then skyrocketed by 54.74% to -$1.8 million in 2024, then soared by 40.3% to -$1.1 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Change in Account Payables are -$1.1 million (Q4 2025), $1.7 million (Q3 2025), and -$1.4 million (Q2 2025).